biostudies-literatureLumley SFWellcome Trust Clinical Career Development FellowNational Institute for Health Research Health Protection Research UnitNIHR Biomedical Research CentreInnovative Medicines InitiativeUK Government’s Department of Health and Social CareMedical Research CouncilKennedy Trust for Rheumatology ResearchNational Institute for Health Research (NIHR)Kennedy TrustWellcome TrustOntario Genomics InstituteWellcome Intermediate Fellowship1208-1219https://www.ebi.ac.uk/biostudies/studies/S-EPMC8994591biostudies-literatureUnknown74(7)<h4>Background</h4>Natural and vaccine-induced immunity will play a key role in controlling the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. SARS-CoV-2 variants have the potential to evade natural and vaccine-induced immunity.<h4>Methods</h4>In a longitudinal cohort study of healthcare workers (HCWs) in Oxfordshire, United Kingdom, we investigated the protection from symptomatic and asymptomatic polymerase chain reaction (PCR)-confirmed SARS-CoV-2 infection conferred by vaccination (Pfizer-BioNTech BNT162b2, Oxford-AstraZeneca ChAdOx1 nCOV-19) and prior infection (determined using anti-spike antibody status), using Poisson regression adjusted for age, sex, temporal changes in incidence and role. We estimated protection conferred after 1 versus 2 vaccinations and fClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaAn Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by Antibody and Vaccination Status.PMC8994591214560/Z/18/ZNIHR200915RP-PG-0514-200151097737HDR-9006115766OGI-055MR/N00065X/1NF-SI-0508-10279KENN202101110110/Z/15/ZNIHR200239Hatton ESzczurkowska JSutton CWright SWheatley MBarot SCrawford-Jones DKirton RPickford HJames TPrentice AThornton EClay HChau KKScreaton GRussell DAbbott MVilca KPerera VFragkouli EWharton VYoung SCogorno GOxford University Hospitals Staff Testing GroupKotowska JO'Sullivan OSanders APikoula MWestlake AMortimore EConstantinides BHosseinzadeh SJones ED'Amato GLashley NWozniak BMoroney RMcGivern EPonting JWolna MToward RTerry RShibu ASims ERoss EOdwin KPereira CCansdale LHatch SBJarratt Barnham IBastable JPeto TEAEconomides GMarsden BDConway-Jones RDrummond BHill SSavage Kde Toledo ZSwann JYang-Turner FMurugathasan AEvans MLayton MEvans SO'Donnell AMSharma ISkelly DFadzillah MDunn LPeck LJSanderson NJarvis SCann KAxten DJesuthasan GFields CSomanathan ARylance-Knight LWolman RJohnson TVaughan ACallard HEdwin CRamage SManji APhillips JMustoe EGates MO'Donnell DCrawley SThompson ZTamblyn MSalvagno CStuart DIFarache Trajano LInnes GWilson JBodo NShimell KLuciw MChmura MLucey MWilkins LTong HDaly EWeeks ECornall RJJackson-Smith HKhulusi BBland LCutteridge JMobbs AJeffery KKalimeris EWalker ASVolk DMartins Ferreira LDavies HBialek AJones EYPill GRitter TGCox VRodger GStreet TLLee KOakley SLee CHopkins SPether DThomas SConlon CPNorris KLawson ECurtis AShaw GMason SButler BCaroll HFerreira CGentry JLumley SFHolland LHuda NJustice AKavanagh JMatthews PCPattrick FClarke JCoward GHolloway BVirgo CAntonucci NHoosdally SWareing SCox SRigler CMadsen TNgoke GPouwels KBWalker TMRavi KWhitty AJ Neville MHowarth AChand MH Foord TButcher LMullins HHobden LTamblin-Hopper PEyre DWBaby ATabirao MPotter TWelbourne ACrook DWMighiu AGrant OWard JCordy SChristott TDoherty GNezhentsev AShabir ZW Fowler PMillard RDobson JKarpe FEbner DStoesser NEAbhari RChohan RBrown JLyden SWarren FFuchs HCameron SOliver JWarren LBrown RPerry SfalseAn Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by Antibody and Vaccination Status.<h4>Background</h4>Natural and vaccine-induced immunity will play a key role in controlling the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. SARS-CoV-2 variants have the potential to evade natural and vaccine-induced immunity.<h4>Methods</h4>In a longitudinal cohort study of healthcare workers (HCWs) in Oxfordshire, United Kingdom, we investigated the protection from symptomatic and asymptomatic polymerase chain reaction (PCR)-confirmed SARS-CoV-2 infection conferred by vaccination (Pfizer-BioNTech BNT162b2, Oxford-AstraZeneca ChAdOx1 nCOV-19) and prior infection (determined using anti-spike antibody status), using Poisson regression adjusted for age, sex, temporal changes in incidence and role. We estimated protection conferred after 1 versus 2 vaccinations and f2022-01-01T00:00:00Z2022 Apr2025-05-29T21:52:31.313Z2025-05-29T21:52:31.313ZS-EPMC89945913421647210.1093/cid/ciab608